QuickLinks
 -- Click here to rapidly navigate through this document
  



 
 

Exhibit 4.7    
    


        THE
SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE BEEN ACQUIRED FOR INVESTMENT AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933. SUCH SECURITIES MAY NOT BE SOLD OR
TRANSFERRED IN THE ABSENCE OF SUCH REGISTRATION UNLESS THE TRANSFER IS IN ACCORDANCE WITH RULE 144 OR SIMILAR RULE OR UNLESS THE COMPANY RECEIVES AN OPINION OF COUNSEL REASONABLY ACCEPTABLE TO IT
STATING THAT SUCH SALE OR TRANSFER IS EXEMPT FROM THE REGISTRATION AND PROSPECTUS DELIVERY REQUIREMENTS OF SAID ACT. 


STOCK
PURCHASE WARRANT

To Purchase Shares of Series D Preferred Stock of

Metabasis Therapeutics, Inc. 


        THIS
CERTIFIES that, for value received,                        (the "Investor"), is entitled, upon the terms and subject to the
conditions hereinafter set forth, at any time on or after the
date hereof and on or prior to October    , 2008 (the "Termination Date"), but not thereafter, to subscribe for and purchase, from Metabasis Therapeutics, Inc., a Delaware
corporation (the "Company"),            shares of Series D Preferred Stock (the "Shares") at an exercise price (the "Exercise Price") of $1.50 per Share. This Warrant is issued at a
purchase price of $0.01 per Share. 


        1.    Title to Warrant.    Prior to the expiration hereof and subject to compliance with applicable laws, this Warrant
and all rights hereunder are transferable, in whole or in part, at the office or agency of the Company, referred to in Section 2 hereof, by the holder hereof in person or by duly authorized
attorney, upon surrender of this Warrant together with the Assignment Form annexed hereto properly endorsed. 


        2.    Exercise of Warrant.    The purchase rights represented by this Warrant are exercisable by the registered holder
hereof, in whole or in part, at any time before the close of business on the Termination Date by the surrender of this Warrant and the Notice of Exercise form annexed hereto duly executed at the
office of the Company in San Diego, California (or such other office or agency of the Company as it may designate by notice in writing to the registered holder hereof at the address of such holder
appearing on the books of the Company), and upon payment of the Exercise Price for the Shares thereby purchased (by cash or by check or bank draft payable to the order of the Company or by
cancellation of indebtedness of the Company to the holder hereof, if any, at the time of exercise in an amount equal to the purchase price of the Shares thereby purchased); whereupon the holder of
this Warrant shall be entitled to receive a certificate for the number of shares of Preferred Stock so purchased. The Company agrees that if at the time of the surrender of this Warrant and purchase
the holder hereof shall be entitled to exercise this Warrant, the shares so purchased shall be and be deemed to be issued to such holder as the record owner of such shares at the close of business on
the date on which this Warrant shall have been exercised as aforesaid. 


        3.    Right to Convert Warrant.    The registered holder hereof shall have the right to convert this Warrant, by the
surrender of this Warrant and the Notice of Conversion form annexed hereto duly executed at the office of the Company in San Diego, California (or such other office or agency of the Company as it may
designate by notice in writing to the registered holder hereof at the address of such holder appearing on the books of the Company), in whole but not in part, at any time before the close of business
on the Termination Date, into the Shares as provided for in this Section 3. Upon exercise of this conversion right, the holder hereof shall be entitled to receive that number of Shares equal to
the quotient obtained by dividing [(A-B)(X)] by (A), where: 



        (A)    = the
Fair Market Value (as defined below) of one (1) Share on the date of conversion of this Warrant. 



1





 

        (B)    = the
Exercise Price for one (1) Share under this Warrant. 


        (X)    = the
number of Shares issuable upon exercise of this Warrant. 




        If
the above calculation results in a negative number, then no Shares shall be issued or issuable upon conversion of this Warrant. 


        "Fair
Market Value" of a Share shall mean: 



        (a)   if
the conversion right is being exercised upon the occurrence of the Company's initial public offering, the initial public offering price per share (before deducting
underwriting commissions and
discounts and offering expenses) multiplied by the number of shares of Common Stock issuable upon conversion of one (1) Share issuable upon exercise of this Warrant; 


        (b)   if
the conversion right is being exercised after, and not in connection with the Company's initial public offering, and: 



        (i)    if
traded on a securities exchange or the Nasdaq National Market, the fair market value shall be deemed to be the average of the closing prices of the securities on such
exchange over the twenty (20) trading day period ending three (3) trading days before the day the current fair market value of the securities is being determined; or 



        (ii)   if
actively traded over-the-counter, the fair market value shall be deemed to be the average of the closing bid or sale prices (whichever are
applicable) over the twenty (20) trading day period ending three (3) trading days before the day the current fair market value of the securities is being determined; and 




        (c)   in
all other cases, the fair value as determined in good faith by the Company's Board of Directors. 




        Upon
conversion of this Warrant, the registered holder hereof shall be entitled to receive a certificate for the number of Shares determined as aforesaid. 



        4.    Issuance of Stock; No Fractional Shares or Scrip.    Certificates for the stock purchased hereunder or issuable
upon conversion hereof shall be delivered to the holder hereof promptly after the date on which this Warrant shall have been exercised or converted as aforesaid. The Company covenants that all Shares
which may be issued upon the exercise of rights represented by this Warrant will, upon exercise of the rights represented by this Warrant, be fully paid and nonassessable and free from all taxes,
liens and charges in respect of the issue thereof (other than taxes in respect of any transfer occurring contemporaneously with such issue). The Company agrees that, if at the time of the surrender of
this Warrant and exercise of the rights represented hereby, the holder hereof shall be entitled to exercise such rights, the Shares so issued shall be and be deemed to be issued to such holder as the
record owner of such Shares as of the close of business on the date on which this Warrant shall have been exercised or converted as aforesaid. No fractional shares or scrip representing fractional
shares shall be issued upon the exercise or conversion of this Warrant. With respect to any fraction of a Share called for upon the exercise or conversion of this Warrant, an amount equal to such
fraction multiplied by the then current price at which each Share may be purchased hereunder shall be paid in cash to the holder of this Warrant. 



        5.    Charges, Taxes and Expenses.    Issuance of certificates for the Shares upon the exercise or conversion of this
Warrant shall be made without charge to the holder hereof for any issue or transfer tax or other incidental expense in respect of the issuance of such certificate, all of which taxes and expenses
shall be paid by the Company, and such certificates shall be issued in the name of the holder of this Warrant or in such name or names as may be directed by the holder of this Warrant;  provided, however,
 that in the event certificates for Shares are to be issued in a name other than the name of the holder of this Warrant, this Warrant
when surrendered for exercise or conversion shall be accompanied 


2





 



by
the Assignment Form attached hereto duly executed by the holder hereof; and provided further, that upon any transfer involved in the issuance or
delivery of any certificates for the Shares, the Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. 


        6.    No Rights as Shareholders.    This Warrant does not entitle the holder hereof to any voting rights or other
rights as a shareholder of the Company prior to the exercise or conversion thereof. 


        7.    Exchange and Registry of Warrant.    This Warrant is exchangeable, upon the surrender hereof by the registered
holder at the above-mentioned office or agency of the Company, for a new Warrant of like tenor and dated as of such exchange. 


        The
Company shall maintain at the above-mentioned office or agency a registry showing the name and address of the registered holder of this Warrant. This Warrant may be surrendered for
exchange, transfer or exercise, in accordance with its terms, at such office or agency of the Company, and the Company shall be entitled to rely in all respects, prior to written notice to the
contrary, upon such registry. 


        8.    Loss, Theft, Destruction or Mutilation of Warrant.    Upon receipt by the Company of evidence reasonably
satisfactory to it of the loss, theft, destruction or mutilation of this Warrant, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it, and upon
reimbursement to the Company of all reasonable expenses incidental thereto, and upon surrender and cancellation of this Warrant, if mutilated, the Company will make and deliver a new Warrant of like
tenor and dated as of such cancellation, in lieu of this Warrant. 



        9.    Saturdays, Sundays, Holidays, etc.    If the last or appointed day for the taking of any action or the
expiration of any right required or granted herein shall be a Saturday or a Sunday or shall be a legal holiday, then such action may be taken or such right may be exercised on the next succeeding day
not a legal holiday. 


        10.    Early Termination and Dilution.    



        (a)    Early Termination.    If at any time after the date hereof (i) the Company's Common Stock is traded on a
securities exchange or the Nasdaq National Market and (ii) the average closing price of such Common Stock over any consecutive twenty (20) trading day period equals or exceeds $4.50
(adjusted to reflect subsequent stock dividends, stock splits or recapitalizations), then within five (5) days following the conclusion of such period the Company shall give the Investor
written notice that the events set forth in clauses (i) and (ii) above have occurred (a "Termination Notice"). If the Warrant has not been exercised or converted by the date thirty
(30) days following the date of the Termination Notice it shall terminate. 



        (b)    Reclassification, etc.    If the Company at any time shall, by subdivision, combination or reclassification of
securities or otherwise, change any of the securities to which purchase rights under this Warrant exist into the same or a different number of securities of any class or classes, this Warrant shall
thereafter be to acquire such number and kind of securities as would have been issuable as the result of such change with respect to the securities which were subject to the purchase rights under this
Warrant immediately prior to such subdivision, combination, reclassification or other change. Without limiting the foregoing, if there shall occur an automatic conversion of shares of Series D
Preferred Stock into Common Stock pursuant to the Company's Amended and Restated Certificate of Incorporation as in effect from time to time, this Warrant shall thereafter be to acquire such number of
shares of Common Stock as would have been issuable as the result of such automatic conversion with respect to the shares of Series D Preferred Stock issuable under this Warrant immediately
prior to such automatic conversion. If the Shares issuable upon the exercise of this Warrant are subdivided or combined into a greater or smaller number of the Shares, the purchase price under this
Warrant shall be proportionately reduced in 



3





 




case
of subdivision of shares or proportionately increased in the case of combination of shares, in both cases by the ratio which the total number of the Shares to be outstanding immediately after
such event bears to the total number of the Shares outstanding immediately prior to such event. 


        (c)    Cash Distributions.    No adjustment on account of dividends on the Shares issuable upon the exercise of this
Warrant will be made to the purchase price under this Warrant. 


        (d)    Authorized Shares.    The Company covenants that, during the period the Warrant is outstanding, it will reserve
from its authorized and unissued Preferred Stock a sufficient number of shares to provide for the issuance of the Shares upon the exercise of any purchase rights under this Warrant. The Company
further covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with the duty of executing stock certificates to execute and issue the necessary
certificates for the Shares upon the exercise of the purchase rights under this Warrant. 


        (e)    Conversion Price Adjustments.    The rate at which the Shares are convertible into shares of Common Stock of
the Company is subject to adjustment as set forth in the Company's Certificate of
Incorporation, as amended. Any adjustment to the conversion rate of the Shares issuable upon the exercise of this Warrant effected prior to any exercise or conversion of this Warrant shall apply to
any Shares thereafter issued pursuant to the terms hereof. 




        11.    Restrictions on Transferability of Securities.    



        (a)    Restrictions on Transferability.    This Warrant, the Shares issuable upon exercise of this Warrant, and the
shares of Common Stock issuable upon conversion of the Shares (collectively the "Securities") shall not be sold, assigned, transferred or pledged except upon the conditions specified in this
Section 11, which conditions are intended to ensure compliance with the provisions of the Securities Act of 1933, as amended (the "Securities Act"). Each holder of any of the Securities will
cause any proposed purchaser, assignee, transferee, or pledgee of the Securities held by such holder to agree to take and hold such Securities subject to the provisions and upon the conditions
specified in this Section 11. 


        (b)    Restrictive Legend.    Each certificate representing the Securities and any other securities issued in respect
of the Securities upon any stock split, stock dividend, recapitalization, merger, consolidation or similar event, shall (unless otherwise permitted by the provisions of Section 11(c) below) be
stamped or otherwise imprinted with a legend in the following form (in addition to any legend required under applicable state securities laws): 



        THE
SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE BEEN ACQUIRED FOR INVESTMENT AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933. SUCH SECURITIES MAY NOT BE SOLD OR
TRANSFERRED IN THE ABSENCE OF SUCH REGISTRATION UNLESS THE TRANSFER IS IN ACCORDANCE WITH RULE 144 OR SIMILAR RULE OR UNLESS THE COMPANY RECEIVES AN OPINION OF COUNSEL REASONABLY ACCEPTABLE TO IT
STATING THAT SUCH SALE OR TRANSFER IS EXEMPT FROM THE REGISTRATION AND PROSPECTUS DELIVERY REQUIREMENTS OF SAID ACT. 




        Each
holder of Securities and each subsequent transferee (hereinafter collectively referred to as a "Holder") consents to the Company making a notation on its records and giving
instructions to any transfer agent of the Securities in order to implement the restrictions on transfer established in this Section 11. 


        (c)    Notice of Proposed Transfers.    Each Holder of a certificate representing the Securities, by acceptance
thereof, agrees to comply in all respects with the provisions of this Section 11(c). Prior 



4





 




to
any proposed sale, assignment, transfer or pledge of any Securities (other than (i) a transfer not involving a change in beneficial ownership, (ii) in transactions involving the
distribution without consideration of Securities by a Holder to any of its partners, or retired partners, or to the estate of any of its partners or retired partners, (iii) a transfer to an
affiliated fund, partnership or company, which is not a competitor of the Company, subject to compliance with applicable securities laws or (iv) transfers in compliance with Rule 144, so
long as the Company is furnished with satisfactory evidence of compliance with such Rule), unless there is in effect a registration statement under the Securities Act covering the proposed transfer,
the Holder thereof shall give written notice to the Company of such Holder's intention to effect such transfer, sale, assignment or pledge. Each such notice shall describe the manner and circumstances
of the proposed transfer, sale, assignment or pledge in sufficient detail, and shall be accompanied, at such Holder's expense, by either (i) an opinion of counsel (who shall, and whose opinion
shall be, addressed to the Company and reasonably satisfactory to the Company) to the effect that the proposed transfer of the Securities may be effected without registration under the Securities Act
or (ii) a "no action" letter from the Securities and Exchange Commission (the "Commission") to the effect that the transfer of such securities without registration will not result in a
recommendation by the staff of the Commission that action be taken with respect thereto, whereupon the Holder of such Securities shall be entitled to transfer such Securities in accordance with the
terms of the notice delivered by such Holder to the Company. Each certificate evidencing the Securities transferred as above provided shall bear, except if such transfer is made pursuant to
Rule 144, the appropriate restrictive legend set forth in Section 11(b) above, except that such certificate shall not bear such restrictive legend if in the opinion of counsel for such
Holder and in the opinion of counsel for the Company such legend is not required in order to establish compliance with any provision of the Securities Act. 



        (d)    Removal of Restrictions on Transfer of Securities.    Any legend referred to in Section 11(b) hereof
stamped on a certificate evidencing the Securities and the stock transfer instructions and record notations with respect to the Securities shall be removed, and the Company shall issue a certificate
without such legend to the Holder of the Securities if the Securities are registered under the Securities Act, or if such Holder provides the Company with an opinion of counsel (which may be counsel
for the Company) reasonably satisfactory to the Company to the effect that a public sale or transfer of such security may be made without registration under the Securities Act or such Holder provides
the Company with reasonable assurances, which may, at the option of the Company, include an opinion of counsel (which may be counsel for the Company) reasonably satisfactory to the Company, that such
security can be sold pursuant to paragraph (k) of Rule 144 (or any successor provision) under the Securities Act. 




        12.    Investment Representations of the Investor.    With respect to the acquisition of any of the Securities, the
Investor hereby represents and warrants to the Company as follows: 



        (a)    Experience.    The Investor has substantial experience in evaluating and investing in private placement
transactions of securities in companies similar to the Company so that it is capable of evaluating the merits and risks of its investment in the Company and has the capacity to protect its own
interests. The
Investor is an "accredited investor" within the meaning of Regulation D promulgated under the Securities Act. 


        (b)    Investment.    The Investor is acquiring the Securities for investment for its own account, not as a nominee or
agent, and not with the view to, or for resale in connection with, any distribution thereof. The Investor understands that the Securities have not been, and will not be, registered under the
Securities Act by reason of a specific exemption from the registration provisions of the Securities Act, the availability of which depends upon, among other things, the bona fide nature of the
investment intent and the accuracy of the Investor's representations as expressed herein. 



5





 




        (c)    Rule 144.    The Investor acknowledges that the Securities must be held indefinitely unless subsequently
registered under the Securities Act, or unless an exemption from such registration is available. The Investor is aware of the provisions of Rules 144 and 144A promulgated under the Securities
Act that permit limited resale of securities purchased in a private placement subject to satisfaction of certain conditions. 


        (d)    No Public Market.    The Investor understands that no public market now exists for any of the securities issued
by the Company and that the Company has made no assurances that a public market will ever exist for the Securities. 


        (e)    Access to Data.    The Investor has had an opportunity to discuss the Company's business, management and
financial affairs with the Company's management and has also had an opportunity to ask questions of the Company's officers, which questions were answered to its satisfaction. 




        13.    Notices.    



        (a)    Notice of Public Offering.    If at any time prior to the exercise or conversion of this Warrant in full the
Company shall determine to effect a registered public offering of its securities, then the Company will give the holder of this Warrant at least thirty (30) days prior written notice of the
proposed effective date of the transaction. 


        (b)    Notice of Record Date.    If at any time prior to the exercise or conversion of this Warrant in full the
Company takes a record of the holders of the Company's stock for the purpose of determining the holders thereof who are entitled to receive any dividend or other distribution, any right to subscribe
for, purchase or otherwise acquire any shares of stock of any class or any other securities or property, or to receive any other right, the Company will give to the holder of this Warrant, at least
thirty
(30) days prior to the date specified therein, written notice specifying the date on which any such record is to be taken for the purpose of such dividend, distribution or right, and the amount
and character of such dividend, distribution or right. 




        14.    Miscellaneous.    



        (a)    Issue Date.    The provisions of this Warrant shall be construed and shall be given effect in all respect as if
it had been issued and delivered by the Company on the date hereof. This Warrant shall be binding upon any successors or assigns of the Company. This Warrant shall be governed in all respects by the
laws of the State of California. 


        (b)    Waivers and Amendments.    With the written consent of the Company and the Investor, the obligations of the
Company and the right of the Investor may be waived (either generally or in a particular instance, either retroactively or prospectively and either for a specified period of time or indefinitely), and
with the same consent the Company and the Investor may enter into a supplementary agreement for the purpose of adding any provisions to or changing in any manner or eliminating any of the provisions
of this Warrant. 


        (c)    Notices.    All notices and other communications required or permitted to be given under this Warrant shall be
in writing and shall be deemed effectively given upon personal delivery, delivery by nationally recognized courier or upon deposit with the United States Post Office (by first class mail, postage
prepaid) addressed as follows: (i) if to the Company, at the address of its principal office in the State of California, or at such other address as the Company shall have furnished the
Investor in writing, and (ii) if to the Investor, to                        , or at such other address as the Investor shall
have furnished the Company in writing. 



        (d)    Survival.    The provisions of Section 11 hereof shall survive the exercise or conversion of this
Warrant and shall remain in effect until such time as the Investor no longer holds Securities. 


        (e)    Binding Effect on Successors.    This Warrant shall be binding upon any corporation succeeding the Company by
merger, consolidation or acquisition of all or substantially all of the Company's assets. All of the covenants and agreements of the Company shall inure to the benefit of successors and assigns of the
holder hereof. 



6





 

        IN
WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized. 



	Dated: October 18, 2001	 	METABASIS THERAPEUTICS, INC.
	

 	
 	

By:	

 
	 	 	 	
 Paul K. Laikind, Chief Executive Officer
	

Acknowledged and agreed:	
 	

 	

 
	

	
 	

 	

 




[SIGNATURE
PAGE TO WARRANT] 


7







 
 

NOTICE OF EXERCISE    
    



	To:
	Metabasis
Therapeutics, Inc. 




        (1)   The
undersigned hereby elects to purchase            shares of Series D Preferred Stock of Metabasis Therapeutics, Inc. pursuant to the terms of the
attached Warrant, and tenders herewith payment of the purchase price in full, together with all applicable transfer taxes, if any. 



        (2)   Please
issue a certificate of certificates representing said shares of Series D Preferred Stock in the name of the undersigned or in such other name as is
specified below: 



	 	 	(Name)	 
	

 	
 	

(Address)	

 





        (3)   The
undersigned represents that the aforesaid shares of Series D Preferred Stock are being acquired for the account of the undersigned for investment and not with
a view to, or for resale in connection with, the distribution thereof and that the undersigned has no present intention of distributing or reselling such shares. 



	(Date)	 	 	 
	 	 	
 (Signature)







 
 

NOTICE OF CONVERSION    
    



	To:
	Metabasis
Therapeutics, Inc. 




        (1)   The
undersigned hereby elects to convert the attached Warrant into such number of shares of Series D Preferred Stock of Metabasis Therapeutics, Inc. as is
determined pursuant to Section 3 of such Warrant, which conversion shall be effected pursuant to the terms of the attached Warrant. 


        (2)   Please
issue a certificate of certificates representing said shares of Metabasis Therapeutics, Inc. Series D Preferred Stock in the name of the undersigned
or in such other name as is specified below: 



	 	 	(Name)	 
	

 	
 	

(Address)	

 





        (3)   The
undersigned represents that the aforesaid shares of Metabasis Therapeutics, Inc. Series D Preferred Stock are being acquired for the account of the
undersigned for investment and not with a view to, or for resale in connection with, the distribution thereof and that the undersigned has no present intention of distributing or reselling such
shares. 



	(Date)	 	 	 
	 	 	
 (Signature)







 
 

ASSIGNMENT FORM    
    


(To
assign the foregoing warrant, execute

this form and supply required information.

Do not use this form to purchase shares.) 


        FOR
VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby assigned to 



	 	 	
 (Please Print)
	

 	
 	

whose address is	

 (Please Print)
	

 	
 	










	 	 	Dated:                        , 20    
	

 	
 	

Holder's Signature:	

 
	 	 	 	

	

 	
 	

Holder's Address:	

 
	 	 	 	

	

 	
 	

 	










	 	 	Signature Guaranteed:	 
	 	 	 	






        NOTE:
The signature to this Assignment Form must correspond with the name as it appears on the face of the Warrant, without alteration or enlargement or any change whatever, and must be
guaranteed by a bank or trust company. Officers of corporations and those acting in a fiduciary or other representative capacity should file proper evidence of authority to assign the foregoing
Warrant. 





 
 

Metabasis Therapeutics, Inc.
  Series D Preferred Stock Financing
  October 18, 2001    
    
    Schedule of Warrantholders    
    



	Purchaser Name and Address
 
	 	Number of Shares of Series D

Preferred Stock Subject to Warrant

	MPM Bioventures II, L.P.

Attn: Luke Evnin

1 Cambridge Center

Cambridge, MA 02142	 	93,789
	MPM Bioventures II-QP, L.P.

Attn: Luke Evnin

1 Cambridge Center

Cambridge, MA 02142	 	849,776
	MPM Bioventures GmbH & Co. Parallel-Beteiligungs KG

Attn: Luke Evnin

1 Cambridge Center

Cambridge, MA 02142	 	299,164
	MPM Asset Management Investors 2000 B LLC

Attn: Luke Evnin

1 Cambridge Center

Cambridge, MA 02142	 	19,566
	InterWest Partners VII, L.P.

3000 Sand Hill Road

Building 3, Suite 255

Menlo Park, CA 94025	 	688,347
	InterWest Investors VII, L.P.

3000 Sand Hill Road

Building 3, Suite 255

Menlo Park, CA 94025	 	32,964
	GC&H Investments

One Maritime Plaza, 20th Floor

San Francisco, CA 94111-3580	 	18,033
	David Hale

16596 Via Lago Azul

Rancho Santa Fe, CA 92067	 	18,033
	DLJ Capital Corp.

3000 Sand Hill Road

Building 3, Suite 170

Menlo Park, CA 94025	 	16,286
	Donaldson, Lufkin & Jenrette Securities Corporation, as nominee for:

    DLJ First ESC, L.P.

    EMA 2001 Plan, L.P.

    CSFB 2001 Investors, L.P.

    Credit Suisse First Boston Private Equity, Inc.

    Docklands 2001 Plan, L.P.

    Paradeplatz 2001 Plan, L.P.

3000 Sand Hill Road

Building 3, Suite 170

Menlo Park, CA 94025	 	77,554
	Sprout Entrepreneurs Fund, L.P.

3000 Sand Hill Road

Building 3, Suite 170

Menlo Park, CA 94025	 	5,295
	Sprout Capital IX, L.P.

3000 Sand Hill Road

Building 3, Suite 170

Menlo Park, CA 94025	 	1,343,488











QuickLinks



Exhibit 4.7



NOTICE OF EXERCISE

NOTICE OF CONVERSION

ASSIGNMENT FORM

Metabasis Therapeutics, Inc. Series D Preferred Stock Financing October 18, 2001 Schedule of Warrantholders